HCHongxin Chen

Hongxin Chen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Hongxin Chen has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Hong Shen

    Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, China

    2 shared publications
  • Feng Xu

    First Clinical Medical College, Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China

    1 shared publication
  • Haijuan Yao

    Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area), Shenyang, China

    1 shared publication
  • Hanyang Lin

    Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area), Shenyang, China

    1 shared publication
  • Hongyu Li

    Department of Gastroenterology, General Hospital of Northern Theater Command (formerly General Hospital of Shenyang Military Area), Shenyang, China

    1 shared publication
  • Jingyi Hu

    Digestive Disease Research Institute, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing, People’s Republic of China

    1 shared publication

Latest Publications

  • Open Access

    Accelerated aging mediates the association between fecal incontinence and mortality: Evidence from the National Health and Nutrition Examination Survey

    by Yizhou Lu, Zixin Yu, Hongxin Chen, Hong Shen

    Objective: This study was designed to examine the relationship between fecal incontinence and accelerated aging, determine its association with mortality risk, and evaluate whether accelerated aging mediates the link between fecal incontinence and mortality. Methods: This cohort study used data from the National Health and Nutrition Examination Survey. Accelerated aging was quantified using phenotypic age acceleration. Multivariable linear regression models, Cox proportional hazards models, and mediation analysis were employed to assess the associations between fecal incontinence, phenotypic age acceleration, and mortality. Results: Among 12,581 United States adults, the overall prevalence of fecal incontinence was 8.38%. Fecal incontinence was positively associated with phenotypic age acceleration (β: 0.98, 95% confidence interval: 0.43, 1.58) and increased risks of all-cause mortality (hazard ratio: 1.24, 95% confidence interval: 1.07, 1.44) and cardiovascular mortality (hazard ratio: 1.28, 95% confidence interval: 1.01, 1.63). Mediation analysis indicated that phenotypic age acceleration accounted for 9.56% of the effect of fecal incontinence on all-cause mortality. Conclusion: Accelerated aging partially mediated the association between fecal incontinence and all-cause mortality in the United States population. These findings suggest new pathways for mitigating the broader health impacts of fecal incontinence.


  • Open Access

    Integration of Multi-Omics and Network Pharmacology Analysis Reveals the Mechanism of Qingchang Huashi Jianpi Bushen Formula in Repairing the Epithelial Barrier of Ulcerative Colitis

    by Yulai Fang, Shichen Min, Yuguang Wu, Feng Xu, Hongxin Chen, Yanan Li, Yizhou Lu, Jingyi Hu, Lei Zhu, Hong Shen

    Purpose: Derivation of Qingchang Huashi formula, named Qingchang Huashi Jianpi Bushen (QCHS_JPBS) formula, has shown significant therapeutic effect on patients with ulcerative colitis (UC). In this study, the potential mechanism of QCHS_JPBS formula in repairing mucosal damage was explored from the perspective of intestinal stem cell (ISCs) differentiation, and potential targets of the QCHS_JPBS formula to improve UC were predicted using network pharmacology analysis. Methods: The therapeutic efficacy of QCHS_JPBS formula was evaluated in a mouse model of 2.5% dextran sulfate sodium (DSS) induced colitis. The effect of this formula on the ISC differentiation was evaluated using tissue transmission electron microscopy, immunofluorescence, and RT-qPCR. The cecal contents were subjected to 16s RNA sequencing analysis and non-target metabolomics analysis using LC-MS/MS. The fecal microbiota transplantation method verified the essential role of gut microbiota in promoting ISC differentiation and repairing mucosal damage. Results: The results indicated that QCHS_JPBS formula suppressed the inflammatory response and repaired the damaged intestinal epithelial barrier in DSS-induced colitis mice. QCHS_JPBS formula promoted ISC differentiation, particularly in the direction of goblet cells. QCHS_JPBS formula restored gut dysbiosis and regulated metabolic disorders in DSS-induced colitis mice. And then, the results of fecal microbiota transplantation indicated that QCHS_JPBS formula promoted differentiation of intestinal stem cells to repair mucosal damage through gut microbiota. Finally, a total of 79 active ingredients of QCHS_JPBS formula were identified based on LC-MS analysis and EGFR, STAT3, SRC, AKT1, and HSP90AA1 were considered as potential therapeutic UC targets of QCHS_JPBS formula based on network pharmacology analysis. Conclusion: The present study demonstrated that QCHS_JPBS formula promoted the differentiation of ISCs through gut microbiota to repair the damaged intestinal epithelial barrier in UC mice.


  • Open Access

    Efficacy of Xuebijing Injection for Acute Pancreatitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

    by Hongxin Chen, Zhaohui Bai, Hongyu Li, Yanyan Wu, Haijuan Yao, Le Wang, Hanyang Lin, Zhenhua Tong, Rolf Teschke, Xingshun Qi

    Background and Aim. Xuebijing injection is a traditional Chinese medicine compound for the improvement of systemic inflammation response. This meta-analysis of randomized controlled trials (RCTs) aimed to explore the clinical efficacy and safety of Xuebijing injection for the treatment of acute pancreatitis (AP). Methods. PubMed Medline, Embase, Cochrane Library, China National Knowledge Infrastructure, China Biology Medicine disc, VIP, and Wanfang databases were searched. The primary outcome was treatment response. The secondary outcomes included changes in clinical and laboratory indicators and incidence of AP-related complications. Meta-analyses were performed by using a random-effect model. Risk ratios (RRs) with 95% confidence intervals (CIs) or weighted mean differences (WMDs) with 95% CIs were calculated. Results. Overall, 23 RCTs were included. The rates of overall (RR = 1.16; 95% CI = 1.12 to 1.20; ) and complete (RR = 1.40; 95% CI = 1.30 to 1.50; ) responses were significantly higher in the Xuebijing injection group. After treatment, the levels of interleukin-6 (WMD = −18.22; 95% CI = −23.36 to −13.08; ), tumor necrosis factor-α (WMD = −16.44; 95% CI = −20.49 to −12.40; ), serum amylase (WMD = −105.61; 95% CI = −173.77 to −37.46; ), white blood cell (WMD = −1.51; 95% CI = −1.66 to −1.36; ), and C-reactive protein (WMD = −11.05; 95% CI = −14.32 to −7.78; ) were significantly lower in the Xuebijing injection group. Abdominal pain (WMD = −1.74; 95% CI = −1.96 to −1.52; ), abdominal distension (WMD = −1.56; 95% CI = −2.07 to −1.04; ), gastrointestinal function (WMD = −2.60; 95% CI = −3.07 to −2.13; ), body temperature (WMD = −2.16; 95% CI = −2.83 to −1.49; ), serum amylase level (WMD = −1.81; 95% CI = −2.66 to −0.96; ), and white blood cell (WMD = −2.16; 95% CI = −2.99 to −1.32; ) recovered more rapidly in the Xuebijing injection group. The incidence of multiple organ dysfunction syndrome (RR = 0.18; 95% CI = 0.05 to 0.62; ), pancreatic pseudocyst (RR = 0.17; 95% CI = 0.04 to 0.77; <svg xmlns:xlink="http://www.w3.org/1999/xlink" xmlns="http://www.w3.org/2000/svg" width="21.918pt"...